SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <invented name> 4.6 mg/24 h transdermal patch <inve
![PDF) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia PDF) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia](https://i1.rgstatic.net/publication/40728794_Safety_and_tolerability_of_transdermal_and_oral_rivastigmine_in_Alzheimer's_disease_and_Parkinson's_disease_dementia/links/0fcfd50acade2d060f000000/largepreview.png)
PDF) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
![PDF) A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease | Daniele Sancarlo and Francesco Panza - Academia.edu PDF) A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease | Daniele Sancarlo and Francesco Panza - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/42340096/mini_magick20190217-11023-1fkiq6w.png?1550464149)
PDF) A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease | Daniele Sancarlo and Francesco Panza - Academia.edu
![Rivastigmine (Exelon) Patch May Complicate Use of Neuromuscular Blocking Drugs - Anesthesia Patient Safety Foundation Rivastigmine (Exelon) Patch May Complicate Use of Neuromuscular Blocking Drugs - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/newsletters/2014/winter/image/exelon_plaster3_opt.jpeg)